Colin Havenar-Daughton

List of Publications by Year
in descending order

46	10,831	117453	243296
papers	citations	34 h-index	44 g-index

56	56	56	14633
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670.	13.7	917
2	Broad sarbecovirus neutralization by a human monoclonal antibody. Nature, 2021, 597, 103-108.	13.7	220
3	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature, 2021, 597, 97-102.	13.7	385
4	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. PLoS Pathogens, 2021, 17, e1009736.	2.1	18
5	Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naÃ¯ve human B cells. Npj Vaccines, 2021, 6, 113.	2.9	40
6	Broad betacoronavirus neutralization by a stem helixâ€“specific human antibody. Science, 2021, 373, 1109-1116.	6.0	262
7	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell, 2020, 183, 1024-1042.e21.	13.5	1,195
8	Systems Biology Methods Applied to Blood and Tissue for a Comprehensive Analysis of Immune Response to Hepatitis B Vaccine in Adults. Frontiers in Immunology, 2020, 11, 580373.	2.2	28
9	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature, 2020, 584, 353-363.	13.7	413
10	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22920-22931.	3.3	42
11	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science, 2020, 370, 950-957.	6.0	504
12	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 2020, 583, 290-295.	13.7	1,695
13	3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelopeâ€“specific plasma cells and humoral immunity in nonhuman primates. Science Immunology, 2020, 5, .	5.6	90
14	Normal human lymph node T follicular helper cells and germinal center B cells accessed via fine needle aspirations. Journal of Immunological Methods, 2020, 479, 112746.	0.6	32
15	A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science, 2019, 366, .	6.0	172
16	Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization. Cell Reports, 2019, 29, 1756-1766.e8.	2.9	47
17	Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant T _{FH} cells. Science Translational Medicine, 2019, 11, .	5.8	90
18	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Immunity, 2019, 50, 241-252.e6.	6.6	153

#	Article	IF	Citations
19	Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. Immunity, 2018, 48, 133-146.e6.	6.6	274
20	BALDR: a computational pipeline for paired heavy and light chain immunoglobulin reconstruction in single-cell RNA-seq data. Genome Medicine, 2018, 10, 20.	3.6	60
21	When designing vaccines, consider the starting material: the human B cell repertoire. Current Opinion in Immunology, 2018, 53, 209-216.	2.4	52
22	The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Science Translational Medicine, 2018, 10, .	5.8	113
23	Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials. Vaccine, 2018, 36, 5671-5677.	1.7	11
24	Tfh cells and <scp>HIV</scp> bnAbs, an immunodominance model of the <scp>HIV</scp> neutralizing antibody generation problem. Immunological Reviews, 2017, 275, 49-61.	2.8	167
25	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity, 2017, 46, 1073-1088.e6.	6.6	286
26	Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5Î± Restrictive Macaques. Journal of Virology, 2017, 91, .	1.5	70
27	Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nature Communications, 2017, 8, 1655.	5.8	142
28	Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. PLoS ONE, 2017, 12, e0186998.	1.1	240
29	Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. Cell Reports, 2016, 17, 2195-2209.	2.9	150
30	Response to Comment on â€œA Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Bloodâ€• Journal of Immunology, 2016, 197, 2558-2558.	0.4	16
31	A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood. Journal of Immunology, 2016, 197, 983-993.	0.4	215
32	Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. Journal of Immunology, 2016, 197, 994-1002.	0.4	130
33	HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science, 2016, 351, 1458-1463.	6.0	382
34	CXCL13 is a plasma biomarker of germinal center activity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2702-2707.	3.3	322
35	Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. PLoS Pathogens, 2016, 12, e1005369.	2.1	241
36	Early Lymphoid Responses and Germinal Center Formation Correlate with Lower Viral Load Set Points and Better Prognosis of Simian Immunodeficiency Virus Infection. Journal of Immunology, 2014, 193, 797-806.	0.4	35

#	Article	IF	Citations
37	Human Circulating PD-1+CXCR3â^'CXCR5+ Memory Tfh Cells Are Highly Functional and Correlate with Broadly Neutralizing HIV Antibody Responses. Immunity, 2013, 39, 758-769.	6.6	790
38	Modulation of SAP dependent T:B cell interactions as a strategy to improve vaccination. Current Opinion in Virology, 2013, 3, 363-370.	2.6	44
39	Development and function of murine RORÎ³t+ iNKT cells are under TGF-Î² signaling control. Blood, 2012, 119, 3486-3494.	0.6	36
40	Cutting Edge: Crucial Role of IL-1 and IL-23 in the Innate IL-17 Response of Peripheral Lymph Node NK1.1â^' Invariant NKT Cells to Bacteria. Journal of Immunology, 2011, 186, 662-666.	0.4	137
41	A rapid strategy to detect the recombined allele in LSLâ€TÎ²RI^{CA} transgenic mice. Genesis, 2010, 48, 559-562.	0.8	12
42	Induction of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses in HIV Vaccine Trial Participants Who Subsequently Acquire HIV-1 Infection. Journal of Virology, 2006, 80, 9779-9788.	1.5	18
43	Correlation between Interferonâ€Î³ Secretion and Cytotoxicity, in Virusâ€Specific Memory T Cells. Journal of Infectious Diseases, 2004, 190, 1692-1696.	1.9	37
44	Moving to Human Immunodeficiency Virus Type 1 Vaccine Efficacy Trials: Defining T Cell Responses As Potential Correlates of Immunity. Journal of Infectious Diseases, 2003, 187, 226-242.	1.9	118
45	Longitudinally Tracked, Rapid and Robust Antigen-Specific Germinal Center Responses in Non-Human Primates after a Single Nanoparticle Vaccine Immunization. SSRN Electronic Journal, 0, , .	0.4	1
46	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , .	13.7	101